| Wockhardt, Sun get US okay for generic drug | 19-NOV-09 |
|
| Indian drug companies Wockhardt and Sun Pharmaceutical Industries have received final approval from the United States Food and Drug Administration (USFDA) to market generic versions of Nicardipine, the hypertension drug. |
|
|
|
|
|
|
|
|
|
| Sun Pharma gains on HC order | 11-NOV-09 |
|
| Sun Pharma touched a high of Rs 1,459 and finally ended at Rs 1,436, up 2% from the previous close. The counter clocked volumes of 234,664 shares on the NSE today. |
|
|
|
| HC stops Zydus drug sale on Sun petition | 11-NOV-09 |
|
| The Madras High Court today directed Ahmedabad-based Zydus Cadila (Cadila Healthcare) not to sell its anti-depressant drug, Venz (venlafaxine), in the domestic market for the time being, based on a trademark complaint from Mumbai-based Sun Pharmaceutical industries. |
|
|
|
|
|
|
|
|
|
|
|
|
| Sun Pharma net profit dips 11.5% | 29-OCT-09 |
|
| Sun Pharmaceutical Industries, India’s largest drug firm in terms of market capitalisation, posted a 11.49 dip in net profit during the quarter ended September 30, compared with the same period last year, due to regulatory issues and the resultant loss of revenue for its US subsidiary, Caraco Pharmaceuticals. |
|
|
|
|
|
|
| Sun Pharma profit dips 11.49% | 28-OCT-09 |
|
| Sun Pharmaceutical Industries, India's largest drug firm in terms of market capitalization, posted a 11.49 dip in net profit during the quarter ended September, compared to the same period last year, due to regulatory issues and the resultant loss of revenue for its US subsidiary Caraco Pharmaceuticals. |
|
|
|
| Bhupesh Bhandari: The new pharmaceutical order | 23-OCT-09 |
|
| The original poster boys of the Indian pharmaceutical industry all seem to be in a spot of bother. Habil Khorakiwala of Wockhardt has sold his animal health, nutrition and hospital businesses to repay the debt on his books. Dilip Shanhgvi of Sun Pharma faces regulatory problems in the US. Caraco Pharmaceuticals, a company he owns in that country, faces a manufacturing ban imposed by the Food & Drug Administration. Dr Reddy’s Laboratories has had to recall products in the US. |
|
|
|
| Sun Pharma rises 2.3% on nod for generic drug | 06-OCT-09 |
|
| Sun Pharmaceutical Industries scrip rose Rs 32 or 2.3 per cent to close the day at Rs 1,429.20 on reports of US Food and Drug Administration’s (USFDA’s) nod for a generic drug. |
|
|
|
| Sensex may be on course to 18k | 04-OCT-09 |
|
| The Sensex ended the holiday-shortened week by gaining 442 points due to the prevailing positive sentiment. While the index touched a fresh 16-month high of 17,196, it also reclaimed the 17,000-mark for two consecutive days on a closing basis. |
|
|
|
| Wkly Tech Analysis: Sensex may be on course to 18k | 04-OCT-09 |
|
| The Sensex ended the holiday-shortened week by gaining 442 points due to the prevailing positive sentiment. While the index touched a fresh 16-month high of 17,196, it also reclaimed the 17,000-mark for two consecutive days on a closing basis. |
|
|
|
Content Guide
